Nanotechnology and mRNA technology, double sword to crack the prostate cancer treatment problem

Although many teams around the world are developing anti-cancer therapies that target highly active proteins or signaling path pathlines in tumor cells, a team of researchers from Bregan Women's Hospital, Boston Children's Hospital and Memorial Sloan Kettering Cancer Center are developing a new treatment that will allow them to treat cancer in a new way. The absence of anti-cancer factors - such as genes such as phosphofatase and tensin homolog, PTEN) and p53 - can help cancer cells grow in an unlimited way, but the missing genes in targeted cancer cells are far more difficult than those that are highly expressed in targeted cancer cells. The team solved this problem by using nanotechnology and the unique properties of mRNA, and by targeting PTEN, they successfully inhibited the growth of preclinical prostate cancer models, the results of which were published recently in Nature Biomedical Engineering, entitled "The Life of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA".
The missing PTEN on chromosome 10 is a well-known tumor suppressor gene, and about half of the metastatic degenerative degenerative prostate cancer and other human cancer patients will have a missing or mutated PTEN, so restoring PTEN's function to treat prostate cancer is a promising but challenging approach.
the new study, researchers used nanotechnology to combine mRNA to successfully solve the problem. They found that packing PTEN mRNA in polymer-lipid impurity nanoparticles modified with polyglycol successfully restored PTEN function in mice with PTEN deficiency. These nanoparticles are stable and less toxic in the serum, and can efficiently trans-infect PTEN mRNA into prostate cancer cells.
, the researchers found that when administered intravenously, the nanoparticles significantly inhibited tumor growth in a variety of models of prostate cancer mice. The researchers also found that mice with PTEN deficiency inhibited pi3K-AKT signaling paths and enhanced cancer cell apoptosis when PTEN function was restored.
, the study provides a new way to combine mRNA technology with nanotechnology to restore tumor anti-cancer gene function to treat tumors. The researchers say that while this study shows potential clinical applications, more research is needed to validate it before entering clinical studies. The researchers also hope to extend this approach to the functional restoration of other cancer-suppressing genes and to further improve the effectiveness of this strategy in combination with other therapies. (Bio Valley)